Targeting CCL2 signaling has attracted a lot of attention for potential clinical applications in the treatment of various types of cancer, atherosclerosis, multiple sclerosis, and type 2 diabetes. This evidence concerns the gene CCL2 and type 2 diabetes mellitus.